Taken together, our results indicate that enzalutamide treatment promotes invasion and migration of prostate cancer cells and DANCR knockdown decreases the promotion, and suggest that DANCR knockdown may be useful for prevention of the potential side effect of AR inhibitors in prostate cancer treatment. The gene discussed is DANCR; the disease is prostate carcinoma.